In compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, IOL Chemicals and Pharmaceuticals has informed that the European Directorate for the Quality of Medicines & Health Care (EDQM) has issued a Certificate of Suitability for Company’s API product ‘Pantoprazole Sodium Sesquihydrate Process-III’ on 14th October 2025. Pantoprazole sodium is a proton pump inhibitor (PPI) that reduces stomach acid and is used to treat conditions such as gastroesophageal reflux disease (GERD), erosive esophagitis, and Zollinger-Ellison syndrome.
The above information is a part of company’s filings submitted to BSE.
